αDC1-TBVA vaccine (Case Comprehensive Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameαDC1-TBVA vaccine (Case Comprehensive Cancer Center)

Drug Alias NameTumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine (Case Comprehensive Cancer Center)

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCase Comprehensive Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesCase Comprehensive Cancer Center

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A